COMMUNIQUÉS West-GlobeNewswire

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
13/03/2024
Company Announcement COPENHAGEN, Denmark; March 13, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document [...]
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
13/03/2024
Company Announcement COPENHAGEN, Denmark; March 13, 2024 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 13, 2024, the Company’s Board of Directors met to constitute itself. Ms. [...]
IRADIMED CORPORATION To Participate at the 36th Annual Roth Conference
13/03/2024
WINTER SPRINGS, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that Roger Susi, the Company's President and Chief Executive Officer, will present at the 36th [...]
Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update
13/03/2024
FARMINGDALE, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the second quarter ended January 31, 2024. Second Quarter Highlights [...]
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
13/03/2024
Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP with participation from new and existing investors including RA Capital Management, Surveyor Capital (a Citadel [...]
Anika Reports Fourth Quarter and Year-End 2023 Financial Results
13/03/2024
Revenue growth and adjusted EBITDA 1 exceeded expectations in the fourth quarter and full year OA Pain Management achieved record annual revenues of $102 million, up 11% in 2023 Announces cost reduction initiatives [...]
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024
13/03/2024
RADNOR, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD [...]
electroCore Announces Fourth Quarter and Full Year 2023 Financial Results
13/03/2024
Record full year 2023 net sales of $ 16.0 million increased 87% over $8.6 million for the full year 2022 Company to host conference call and webcast today, March 13, 2024 at 4:30pm EST ROCKAWAY, N.J., March 13, 2024 ( [...]
Jushi Holdings Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
13/03/2024
Maintained Strong Gross Profit Margin of 40.2% in Q4 2023 and 43.1% for FY 2023 Net Loss of $18.0 Million in Q4 2023 Compared to $139.9 Million in Q4 2022 Improved Adjusted EBITDA and Adjusted EBITDA Margin to $11.3 M [...]
PepGen to Participate in Upcoming Investor Conferences
13/03/2024
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of [...]
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
13/03/2024
Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical endpoints [...]
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
13/03/2024
BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on [...]
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024
13/03/2024
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, [...]
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update
13/03/2024
On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024 Initiated enrollment in PIVOT-PO, a pivotal Phase 3 [...]
scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
13/03/2024
Generated 4Q 2023 net FUROSCIX ® revenue of $6.1 million, at the upper end of the range provided in January and representing sequential growth of 61% from $3.8 million in 3Q 2023 Generated full-year net FUROSCIX ® [...]
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
13/03/2024
– Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA ® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 – – CIMERLI ® net sales of $52.4 million in [...]
Epic Bio to Present at the Upcoming Charles River Cell and Gene Therapy Summit
13/03/2024
SOUTH SAN FRANCISCO, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Epic Bio , a leading epigenetic editing company that plans to dose its first patients later this year, today announced that Amber Salzman, Ph.D., chief [...]
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D
13/03/2024
Daix (France), Long Island City (New York, United States), March 13, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small [...]
Inventiva annonce la présentation des résultats de son étude clinique de Phase IIa LEGEND combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de DT2
13/03/2024
Daix (France), Long Island City (New York, États-Unis), le 13 mars 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites [...]

Pages